Ser-aí-após-o-diagnóstico-de-câncer-de próstata: possibilidades de cuidado em saúde do homem

Abstract

Qualitative research based on Heideggerian's theoretical, philosophical and methodological approach, in order to unveil the lived experiences of men after the diagnosis of prostate cancer. The project was submitted to the Research Ethics Committee of the Federal University of Juiz de Fora, for ethical and legal issues according to National Health Council Resolution n° 466/2012 and was accepted under n° 525.352. The research setting was a teaching hospital at Zona da Mata Mineira and the subjects were fifteen men diagnosed with prostate cancer. Interviews were conducted through phenomenological interviews and some units of signification have emerged from essential structures. Vague and median understanding, the first methodical moment, allowed the development of the central research thread towards the interpretive hermeneutic analysis, called the second methodical moment. In light of Heidegger's thought, it has been shown that the moment this man is diagnosed with prostate cancer he feels threatened by the disease and its consequences, reporting an improper anguish with fear, dread, horror and terror. The being-thereafter- diagnosis-of-prostate-cancer in his facticity reveals an inauthenticity determined by the impersonal being exposed to chattering and the ambiguity over all the aspects related to prostate cancer leading him to decay. The invisibilities of professionals and health services characterized by inauthenticity and impersonality were present in delivering care to man. Regarding the senses unveiled this study emphasizes the contribution provided to improve the quality care delivered to men showing how necessary it is to consider not only physical but emotional, social and spiritual aspects, in view of current Public Policies on Male Health. Furthermore these insights and many others may enable new sources of assistance targeting men’s health, helping to meet their needs when they have to face diagnosis of prostate cancer.